A Phase 1/2, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Immunogenicity, and Efficacy of a Chlamydia Trachomatis mRNA Vaccine Candidate in Adults Aged 18 to 29 Years
Latest Information Update: 07 Apr 2025
At a glance
- Drugs Chlamydia trachomatis vaccine Sanofi (Primary) ; Chlamydia trachomatis vaccine
- Indications Chlamydial infections
- Focus Adverse reactions
- Sponsors Sanofi
- 30 Mar 2025 Status changed from not yet recruiting to recruiting.
- 26 Mar 2025 New trial record